StockData

Mirum Pharmaceuticals vs Travere Therapeutics

MIRM and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MIRM and TVTX compare

Mirum Pharmaceuticals is the larger company, worth 1.2 times as much as Travere Therapeutics ($6.0B against $4.8B).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 44.0% for Mirum Pharmaceuticals).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −139% at Mirum Pharmaceuticals.

Travere Therapeutics scores higher on the StockData Score (6 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMIRMTVTX
Size and price
Market cap$6.0B$4.8B
Share price$91.95$51.10
Change, 1 year28.7%48.1%
Change, 5 years586%76.0%
Beta (5Y)0.611.91
Employees372497
StockData Score
Total score56 (better)
Valuation score00
Growth score33
Performance score12 (better)
Health score11
Dividend score00
Valuation
P/S9.7×8.1× (better)
P/B–196×
EV/EBITDA–197×
FCF yield−3.8%–
Fair value–$6.01
Margin of safety–−751%
Growth
Revenue growth (TTM)44.0%77.1% (better)
Revenue growth, 5Y average–19.9%
Profitability
Gross margin–98.6%
Operating margin−135%−6.8% (better)
Net margin−139%−7.4% (better)
FCF margin−37.0%–
Return on equity−703%−152% (better)
Financial health
Interest coverage−62.1×−4.3× (better)
Current ratio2.864.05 (better)
Altman Z-score−0.222.29 (better)
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions110%112%
Held by insiders9.2%1.6%
Insider net buying, 12 months−$32.8M (better)−$110M
Short interest, % of float11.1%10.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.